XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Equity
 6 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
Equity EquityStock-Based Compensation
Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:
Three months ended
June 30,		Six months ended
June 30,
(in millions)2023202220232022
Cost of products sold$9 $6 $29 $25 
Research and development57 40 174 147 
Selling, general and administrative113 61 289 241 
Pre-tax compensation expense179 107 492 413 
Tax benefit(30)(21)(85)(77)
After-tax compensation expense$149 $86 $407 $336 
Stock Options
During the six months ended June 30, 2023, primarily in connection with the company's annual grant, AbbVie granted 0.6 million stock options with a weighted-average grant-date fair value of $29.89. As of June 30, 2023, $9 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.
RSUs and Performance Shares
During the six months ended June 30, 2023, primarily in connection with the company's annual grant, AbbVie granted 5.8 million RSUs and performance shares with a weighted-average grant-date fair value of $149.86. As of June 30, 2023, $802 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.
Cash Dividends
The following table summarizes quarterly cash dividends declared during 2023 and 2022:
20232022
Date DeclaredPayment Date
Dividend Per Share
Date Declared
Payment Date
Dividend Per Share
06/22/2308/15/23$1.48 10/28/2202/15/23$1.48 
02/16/2305/15/23$1.48 09/09/2211/15/22$1.41 
06/23/2208/15/22$1.41 
02/17/2205/16/22$1.41 
Stock Repurchase Program
The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.
On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 10 million shares for $1.6 billion during the six months ended June 30, 2023 and 8 million shares for $1.1 billion during the six months ended June 30, 2022. AbbVie's remaining stock repurchase authorization was approximately $4.8 billion as of June 30, 2023.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2023:
(in millions)Foreign currency
translation adjustments
Net investment
hedging activities
Pension 
and post-employment
benefits
Cash flow hedging
activities		Total
Balance as of December 31, 2022$(1,513)$464 $(1,458)$308 $(2,199)
Other comprehensive income (loss) before reclassifications178 (168)39 8 57 
Net gains reclassified from accumulated other comprehensive loss— (45)(3)(62)(110)
Net current-period other comprehensive income (loss)178 (213)36 (54)(53)
Balance as of June 30, 2023$(1,335)$251 $(1,422)$254 $(2,252)
Other comprehensive loss for the six months ended June 30, 2023 included foreign currency translation adjustments totaling a gain of $178 million principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a loss of $213 million.
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2022:
(in millions)Foreign currency
translation adjustments
Net investment
hedging activities
Pension 
and post-employment
benefits		Cash flow hedging
activities		Total
Balance as of December 31, 2021$(570)$(91)$(2,546)$308 $(2,899)
Other comprehensive income (loss) before reclassifications(1,054)696 (11)45 (324)
Net losses (gains) reclassified from accumulated other comprehensive loss— (30)87 (30)27 
Net current-period other comprehensive income (loss)(1,054)666 76 15 (297)
Balance as of June 30, 2022$(1,624)$575 $(2,470)$323 $(3,196)
Other comprehensive loss for the six months ended June 30, 2022 included foreign currency translation adjustments totaling a loss of $1.1 billion principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling a gain of $666 million.
The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
Three months ended
June 30,		Six months ended
June 30,
(in millions) (brackets denote gains)2023202220232022
Net investment hedging activities
Gains on derivative amount excluded from effectiveness testing(a)
$(29)$(24)$(57)$(38)
Tax expense6 6 12 8 
Total reclassifications, net of tax$(23)$(18)$(45)$(30)
Pension and post-employment benefits
Amortization of actuarial losses and other(b)
$(1)$56 $(3)$111 
Tax benefit— (12)— (24)
Total reclassifications, net of tax$(1)$44 $(3)$87 
Cash flow hedging activities
Gains on foreign currency forward exchange contracts(c)
$(26)$(18)$(56)$(26)
Gains on treasury rate lock agreements(a)
(6)(6)(12)(12)
Gains on cross-currency swap contracts(d)
(8)— (8)— 
Losses on interest rate swap contracts(a)
— 1 — 3 
Tax expense 9 4 14 5 
Total reclassifications, net of tax$(31)$(19)$(62)$(30)
(a) Amounts are included in interest expense, net (see Note 8).
(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).
(c) Amounts are included in cost of products sold (see Note 8).
(d) Amounts are included in net foreign exchange loss (see Note 8).